Board

Paul MacLeman

CHAIRMAN

Paul has over 25 years’ experience across all phases of the life sciences sector. With a career-spanning veterinary practice, pharmaceutical development and manufacturing, biotechnology, diagnostics and finance, Paul has expertise in capital management, business development, technology commercialisation and sales & marketing globally. Paul has launched products using both in-house and outsourced sales staff in Australia and the US. He has founded life sciences start-ups in the biologics area and worked in investment banking focusing on the analysis and financing of technology companies. Paul has previously served as Chairman, Director or Managing Director/CEO of several VC funded, ASX, NASDAQ, CSE and TSX listed companies and has driven a number of IPOs. Paul Chaired the Industry Review Committee for the Pharmaceutical Manufacturing National Training Package for the AISC for approximately 10 years prior to the establishment of the new Jobs and Skills Councils and advises the new formed Manufacturing Industry Skills Alliance. He is also an expert advisor to PharmaVentures plc. (Oxford, UK) and serves on a number of other NFP and government advisory groups. He currently Chairs or is a Non-Executive Director of a number of public unlisted and private companies. Paul is the Executive Chairman of Island Pharmaceuticals Limited (ASX:ILA).

Tim Oldham PhD

CEO & MANAGING DIRECTOR

Tim has more than 20 years of life sciences business development, alliance management, portfolio and product development, and commercialisation experience in Europe, Asia and Australia, with a particular focus on biologics, cell and gene therapies and pharmaceutical products. Tim was appointed CEO and MD in October 2019. Immediately prior to this, he was Executive Leader of Tijan Ventures, an advisory business focussed on growing life sciences companies through strategic advisory and interim CEO, executive and non-executive leadership services, with a particular focus on biologics, cell and gene therapies and immunotherapy. Previous roles include CEO and Managing Director of Cell Therapies Pty Ltd, a leading contract manufacturer and distributor cellular therapies in Asia Pacific, President of Asia Pacific for Hospira, Inc., and a variety of senior management roles with Mayne Pharma Ltd prior to its acquisition by Hospira. Prior to this, Tim was an engagement manager with McKinsey & Company. Industry leadership roles include currently serving as a Director of BioMelbourne Network Inc and terms as chairman of the European Generic Medicines Association Biosimilars and Biotechnology Committee, a Director of the Alliance for Regenerative Medicine and a Director of the Generic Medicines Industry Association. He is a Non-executive Director at Acrux Ltd (ASX:ACR).

Robert Peach PhD

NON-EXECUTIVE DIRECTOR

Dr Peach has over 25 years of drug discovery and development experience in the Pharmaceutical and Biotechnology industry.  In 2009 he co-founded Receptos, becoming Chief Scientific Officer and raising $59M in venture capital and $800M in an IPO and three subsequent follow-on offerings.  In August 2015 Receptos was acquired by Celgene for $7.8B.  Robert held senior executive and scientific positions in other companies including Apoptos, Biogen Idec, IDEC and Bristol-Myers Squibb, supporting in-licensing, acquisition and venture investments.  His extensive drug discovery and development experience in autoimmune and inflammatory diseases, and cancer has resulted in multiple drugs entering clinical trials and 3 registered drugs.  He currently serves on the Board of Directors of Innate Immunotherapeutics and Avalia Immunotherapies and is a consultant for several other biotechnology companies. Robert is the co-author of 70 scientific publications and book chapters, and 17 patents.  He was educated at the University of Canterbury and the University of Otago, New Zealand.

David Fuller

NON-EXECUTIVE DIRECTOR

David has 30 years experience in pre-clinical, clinical development, medical and regulatory affairs with a specialisation in the early phase development of biological molecules. David has an impressive record of developing and commercialising new products and establishing and nurturing businesses in complex international environments. He has led five product approvals in the United States (US) and European Union (EU) for orphan and major market products, together with multiple Regulatory Agency (US/EU) interactions including Investigational New Drug (IND) applications. David has designed and executed multiple Phase I – III studies in US, EU and Asia across multiple therapeutic areas. David is currently Senior Vice President, Clinical Development, Oncology Business Unit, Syneos Health where he has overall responsibility for the strategy and growth of the Oncology Business Unit in Asia Pacific. He is also a Non-Executive Director at EpiAxis Therapeutics Pty Ltd, a former Non-Executive Director of Linear Clinical Research Ltd – a Perth based clinical trials facility – and a former Chair of Dimerix Ltd (ASX:DXB). David holds Bachelor of Medicine/Bachelor of Surgery and Bachelor of Pharmacy degrees from University of Sydney.

Iain Ross

NON-EXECUTIVE DIRECTOR

Iain is a seasoned executive and company director with over 35 years of experience in the life sciences and technology sectors. Throughout his career, he has successfully completed multiple financing transactions and brings over three decades of expertise in cross-border management as Chairman and CEO. This has provided him with substantial knowledge of international capital markets and structuring growth strategies. Iain has been instrumental in leading and participating in eight Initial Public Offerings (IPOs) and has direct experience in mergers and acquisitions across Europe, the US, and the Pacific Rim.

Currently, Iain serves as Chairman of NASDAQ-listed Silence Therapeutics (NASDAQ: SLN) and ReNeuron Group plc. He is also a Non-Executive Director at Tern plc, a technology investment firm listed on London’s Alternative Investment Market (AIM), and FivepHusion Limited, a private oncology company based in Sydney. His previous executive roles include leadership positions at global organisations such as Sandoz, Hoffman-La Roche, Reed Business Publishing, and Celltech Group.

He holds a Bachelor of Science and is a Fellow in Biochemistry from Royal Holloway, University of London. Additionally, he is a Chartered Director and Fellow of the Institute of Directors.

Michelle Burke

NON-EXECUTIVE DIRECTOR

Michelle brings over 30 years of experience in the healthcare and life sciences sectors, with expertise spanning cell therapies, strategy, and governance. Her extensive biopharmaceutical, biotechnology, and business strategy acumen has benefited the numerous healthcare institutions where she has served as a Non-Executive Director and Chair.

Currently, Michelle is a Non-Executive Director at Cell Therapies Pty Ltd, a globally active Australian company specialising in the commercial development and manufacturing of cell therapy, gene therapy, regenerative medicine, and cellular immunotherapy products. She also serves as a Non-Executive Director for the Olivia Newton-John Cancer Research Institute.

Michelle’s past roles include serving as Chair and Non-Executive Director of AusBiotech, Australia’s peak industry body for life sciences, and holding senior commercial and corporate affairs positions at global healthcare leaders Bristol-Myers Squibb and SmithKline Beecham (now GSK).

In addition to her directorships, Michelle is a member of the Pharmaceutical Benefits Advisory Committee (an independent expert body appointed by the Australian Government) and provides consulting services to companies, governments, and academic institutions, focusing on commercialisation, business planning, and healthcare policy.

She holds a Bachelor of Science (Honours) from Monash University and is a graduate of the Australian Institute of Company Directors (GAICD).

Cameron Jones

COMPANY SECRETARY

Cameron Jones is a Chartered Accountant and holds a Certificate in Governance (Practice) from the Governance Institute of Australia and assumes responsibility for Australian Securities and Investments (ASIC) reporting, ASX compliance and reporting, planning and execution of annual reporting and shareholder meetings as well as Chief Financial Officer of AdAlta. Cameron is also a Director of Bio101Group Pty Ltd, a wholly owned subsidiary of Biotech Capital Limited and has previously worked at Pitcher Partners.